GlaxoSmithKline Trading Services Limited — China drug registrations and re-registration deadlines
8 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest re-registration deadline: 2027-07-03.
| Approval number | Product | Certificate expires | Re-registration deadline (Art. 82) |
|---|---|---|---|
| 国药准字HJ20180005 | ANORO 乌美溴铵维兰特罗吸入粉雾剂 | 2028-01-03 | 2027-07-03 |
| 国药准字HJ20180044 | Fluticasone Furoate and Vilanterol Trifenatate Powder for Inhalation (Ⅱ) 糠酸氟替卡松维兰特罗吸入粉雾剂（Ⅱ） | 2028-06-06 | 2027-12-06 |
| 国药准字HJ20180045 | Fluticasone Furoate and Vilanterol Trifenatate Powder for Inhalation (Ⅲ) 糠酸氟替卡松维兰特罗吸入粉雾剂（Ⅲ） | 2028-06-06 | 2027-12-06 |
| 国药准字HJ20160515 | Avodart 度他雄胺软胶囊 | 2029-05-12 | 2028-11-12 |
| 国药准字SJ20260023 | EXDENSUR 德莫奇单抗注射液 | 2031-03-24 | 2030-09-24 |
| 国药准字SJ20260024 | EXDENSUR 德莫奇单抗注射液 | 2031-03-24 | 2030-09-24 |
| 国药准字SJ20260029 | BLENREP 注射用玛贝兰妥单抗 | 2031-04-13 | 2030-10-13 |
| 国药准字SJ20260030 | BLENREP 注射用玛贝兰妥单抗 | 2031-04-13 | 2030-10-13 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.